Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 57, Issue 2, 2011, Pages 268-274

  Smith, Malcolm A ^a   Maris, John M ^b   Lock, Richard ^c   Kolb, E Anders ^d   Gorlick, Richard ^e   Keir, Stephen T ^f   Carol, Hernan ^c   Morton, Christopher L ^g   Reynolds, C Patrick ^h   Kang, Min H ^h   Houghton, Peter J ⁱ  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^d NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^e CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

ⁱ NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Developmental therapeutics; Polyamine; Preclinical testing

Indexed keywords

ANTINEOPLASTIC AGENT; PG 11047; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG EXPOSURE; DRUG SCREENING; EPENDYMOMA; EWING SARCOMA; FEMALE; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MITOSIS INHIBITION; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; RHABDOID TUMOR; RHABDOMYOSARCOMA; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASMS; SPERMINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958797801     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22797     Document Type: Article

References (26)

1. Reddy VK, Valasinas A, Sarkar A, et al. Conformationally restricted analogues of 1N, 12N-bisethylspermine: Synthesis and growth inhibitory effects on human tumor cell lines. J Med Chem 1998; 41: 4723-4732.
2. Casero RA, Jr., Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007; 6: 373-390.
3. Van Nieuwenhove S, Schechter PJ, Declercq J, et al. Treatment of Gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans R Soc Trop Med Hyg 1985; 79: 692-698.
4. Sjoerdsma A, Schechter PJ. Eflornithine for African sleeping sickness. Lancet 1999; 354: 254.
5. Schechter PJ, Sjoerdsma A. Difiuoromethylornithine in the treatment of African trypanosomiasis. Parasitol Today 1986; 2: 223-224.
6. Meyskens FL, Jr., McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008; 1: 32-38.
7. Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 2000; 6: 3878-3884.
8. Prados MD, Wara WM, Sneed PK, et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001; 49: 71-77.
9. Levin VA, Hess KR, Choucair A, et al. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003; 9: 981-990.
10. Hacker A, Marton LJ, Sobolewski M, et al. In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells. Cancer Chemother Pharmacol 2008; 63: 45-53.
11. Kuo WL, Das D, Ziyad S, et al., A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med 2009; 7: 77.
12. Dredge K, Kink JA, Johnson RM, et al. The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer. Cancer Chemother Pharmacol 2009; 65: 191-195.
13. Nilsson JA, Maclean KH, Keller UB, et al. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. Mol Cell Biol 2004; 24: 1560-1569.
14. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993; 90: 7804-7808.
15. Hogarty MD, Norris MD, Davis K, et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 2008; 68: 9735-9745.
16. Rounbehler RJ, Li W, Hall MA, et al. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 2009; 69: 547-553.
17. Wallick CJ, Gamper I, Thorne M, et al. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 2005; 24: 5606-5618.
18. Nilsson JA, Keller UB, Baudino TA, et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer cell 2005; 7: 433-444.
19. Frgala T, Kalous O, Proffitt RT, et al. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 886-897.
20. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008; 50: 37-45.
21. 50 estimation. Pharm Stat 2010; DOI: 10.1002/pst.426.
22. Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988; 48: 4189-4195.
23. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-3914.
24. Houghton PJ, Morton CL, Tucker C, et al. The Pediatric Preclinical Testing Program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.
25. Ignatenko NA, Yerushalmi HF, Pandey R, et al. Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. Cancer Genomic Proteomic 2009; 6: 161-175.
26. Evageliou NF, Hogarty MD. Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma. Clin Cancer Res 2009; 15: 5956-5961.